Dolly A. Vance
2017
In 2017, Dolly A. Vance earned a total compensation of $1.1M as Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary at Rigel Pharmaceuticals, a 1% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $244,907 |
|---|---|
| Option Awards | $393,545 |
| Salary | $489,814 |
| Other | $1,794 |
| Total | $1,130,060 |
Vance received $489.8K in salary, accounting for 43% of the total pay in 2017.
Vance also received $244.9K in non-equity incentive plan, $393.5K in option awards and $1.8K in other compensation.
Rankings
In 2017, Dolly A. Vance's compensation ranked 8,393rd out of 14,666 executives tracked by ExecPay. In other words, Vance earned more than 42.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,393 out of 14,666 | 43rd |
Division Manufacturing | 3,181 out of 5,768 | 45th |
Major group Chemicals And Allied Products | 1,054 out of 2,074 | 49th |
Industry group Drugs | 831 out of 1,730 | 52nd |
Industry Pharmaceutical Preparations | 650 out of 1,329 | 51st |
Source: SEC filing on April 4, 2018.
Vance's colleagues
We found five more compensation records of executives who worked with Dolly A. Vance at Rigel Pharmaceuticals in 2017.
2017
Raul Rodriguez
Rigel Pharmaceuticals
Chief Executive Officer
2017
Ryan Maynard
Rigel Pharmaceuticals
Chief Financial Officer
2017
Anne-Marie Duliege
Rigel Pharmaceuticals
Chief Medical Officer
2017
Eldon Mayer
Rigel Pharmaceuticals
Executive Vice President, Chief Commercial Officer
2017
Esteban Masuda
Rigel Pharmaceuticals